Cintra RM, Nogueira AC, Bonilha I, et al. - Researchers herein investigated the effect of anti-hyperglycemic drugs as well as their association on hospitalization due to heart failure (HHF). Data were obtained from 40 randomized controlled trials reporting HHF. Findings of random additive-effects network meta-analysis revealed that metformin, sulfonylureas, glucagon-like peptide-1 receptor-agonist and dipeptidyl peptidase 4 inhibitors (DPP4i) were neutral on the risk of HHF. The results demonstrated that sodium glucose co-transporter 2 inhibitors as monotherapy or in combination with DPP4i caused decrease in the risk of HHF, whereas the risk was elevated in relation to the use of thiazolidinediones as monotherapy or in combination. An additive impact of decreasing HHF was shown to be conferred by glucose-lowering.